证券代码：300110 证券简称：华仁药业 公告编号：2026-006 华仁药业股份有限公司 关于乳酸钠林格注射液取得药品补充申请批准通知书的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）收到国家药品监督管理局 核准签发的乳酸钠林格注射液（规格：500ml）《药品补充申请批准通知书》， 该药品通过仿制药质量和疗效一致性评价。具体情况公告如下： 一、药品基本情况 1．药品名称 药品通用名称：乳酸钠林格注射液 英文名/拉丁名：Sodium Lactate Ringer's Injection 2．剂型：注射剂 3．注册分类：化学药品 4．规格：500ml 5．包装规格：20 袋/箱 6．原药品批准文号：国药准字 H20023794 地址：青岛高科技园区株洲路 187 号 8．申请内容：注射剂仿制药质量和疗效一致性评价，其他变更事项包括：1. 变更药品处方及生产工艺（含生产批量变更）；2. 变更药品质量标准；3. 修订 药品说明书。 9．审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药 品医疗器械 ...

华仁药业股份有限公司 简式权益变动报告书 上市公司名称：华仁药业股份有限公司 股票简称：华仁药业 股票代码：300110 股票上市地点：深圳证券交易所 信息披露义务人：华仁世纪集团有限公司 住所/通讯地址：山东省青岛市市南区山东路2号甲25层GH 一致行动人：梁福东 住所/通讯地址：山东省青岛市 权益变动性质：股份减少，持股比例降至5%以下 签署日期：二〇二六年三月四日 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》《 上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号— —权益变动报告书》及其他相关法律法规和规范性文件编写。 二、信息披露义务人及其一致行动人签署本报告书已获得必要的授权和批准， 其履行亦不违反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证 券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报告书 已全面披露信息披露义务人及其一致行动人在华仁药业股份有限公司中拥有权益的 股份变动情况。截至本报告书签署日，除本报告书披露的持股信息外，信息 ...

证券代码：300110 证券简称：华仁药业 公告编号：2026-005 华仁药业股份有限公司 关于持股 5%以上股东持股比例变动至 5%以下暨权益变动 的提示性公告 股东华仁世纪集团有限公司保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。本公司及董事会全体成员保证公 告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次权益变动为股东持股比例减少所致，不触及要约收购。 2、本次权益变动不会导致公司控股股东和实际控制人发生变化，不会影响 公司的治理结构和持续经营。 3、本次权益变动后，华仁世纪集团有限公司及其一致行动人梁福东先生持 有公司股份59,110,605股，占公司总股本比例为4.999996%，不再是公司持股5% 以上股东。 华仁药业股份有限公司（以下简称"华仁药业""上市公司"或"公司"）于2026 年3月4日收到股东华仁世纪集团有限公司（以下简称"华仁世纪集团"）出具的 《简式权益变动报告书》。华仁世纪集团于2019年12月19日-2026年3月3日期间 因增减持公司股份累计导致持股比例减少6.50%，本次权益变动后，华仁世纪集 团及其一致行动人梁福东先生合计 ...

公司与本公告同日披露了《关于持股5%以上股东持股比例变动至5%以下暨 权益变动的提示性公告》（公告编号：2026-005）及《简式权益变动报告书》， 华仁世纪集团及其一致行动人持有公司股份比例降至4.999996%，不再是公司持 股5%以上股东。 近日，公司收到华仁世纪集团《关于减持华仁药业股份计划实施结果的告知 函》，华仁世纪集团上述减持计划期限已届满。现将具体情况公告如下： 华仁药业股份有限公司 关于股东减持计划实施情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 华仁药业股份有限公司（以下简称"公司"）于2025年11月13日披露了股东华 仁世纪集团有限公司（以下简称"华仁世纪集团"）《关于持股5%以上股东减 持计划预披露的公告》（公告编号：2025-071），华仁世纪集团计划自减持计划 公告之日起十五个交易日后的三个月内通过集中竞价交易方式、大宗交易方式减 持不超过公司总股本3%的股份，即不超过35,466,300股，其中通过集中竞价交易 方式减持不超过公司总股本1%的股份，即不超过11,822,100股，通过大宗交易方 式减持股数不超过公司 ...

证券代码：300110 证券简称：华仁药业 公告编号：2026-003 本次中选产品 2024 年合计销售收入为 2085.53 万元，占公司 2024 年营业收 入总额的 1.54%（数据已经审计）；2025 年前三季度合计销售收入为 585.34 万 中选企业 中选产品 适应症 规格 安徽恒星制 药有限公司 多索茶碱注 射剂 适用于支气管哮喘，慢性喘息性支 气管炎及其他支气管痉挛引起的 呼吸困难。 10ml:0.1g*1 支/支 安徽恒星制 药有限公司 左氧氟沙星 注射剂型 适用于医院获得性肺炎、社区获得 性肺炎、急性细菌性鼻窦炎、慢性 支气管炎的急性细菌性发作、复杂 性皮肤及皮肤结构感染、非复杂性 皮肤及皮肤软组织感染、慢性细菌 性前列腺炎、复杂性尿路感染、急 性肾盂肾炎、非复杂性尿路感染及 吸入性炭疽（暴露后）等的治疗。 20ml︰0.5g（按 C18H20FN3O4 计）*1 支/支 一、中选产品的基本情况 元，占公司 2025 年前三季度营业收入总额的 0.60%（数据未经审计）。 本次接续采购由全国各省（自治区、直辖市）和新疆生产建设兵团组成采购 联盟，委托江苏省、河南省和广东省牵头，对原国家组 ...

Core Viewpoint - Huarun Pharmaceutical's stock price has recently increased, indicating active financing transactions and heightened market participation [1] Stock Performance - On February 24, 2026, Huarun Pharmaceutical's stock closed at 3.29 yuan, with a daily increase of 2.81% and a trading volume of 91.76 million yuan [1] - The net outflow of main funds was 6.517 million yuan, while the financing purchase amount reached 13.2529 million yuan, resulting in a net financing purchase of 3.5662 million yuan [1] - The financing balance stood at 299 million yuan, with 11 out of the last 20 trading days showing net purchases, reflecting high market participation [1] - As of February 25, 2026, the stock price further rose to 3.32 yuan, with a daily increase of 0.91% and a trading volume of 52.81 million yuan, resulting in a turnover rate of 1.34% [1] Recent Events - As of February 10, 2026, the number of Huarun Pharmaceutical shareholders was 39,300, an increase of 400 from January 30, representing a growth rate of 1.03%, although the average shareholding per account slightly decreased [1] - On the same day, the company's margin trading balance increased by 1.21% compared to the previous day, indicating enhanced activity [1]

Core Viewpoint - The company, Huaren Pharmaceutical, is expected to report a significant loss in 2025 due to substantial goodwill impairment related to two subsidiaries, while also expanding its renal business capacity and experiencing executive changes [1][2]. Financial Performance - The company forecasts a net profit attributable to shareholders of between -480 million yuan and -360 million yuan for 2025, primarily due to goodwill impairment of 440 million to 540 million yuan related to subsidiaries Anhui Hengxing Pharmaceutical and Guangxi Yuyuan Pharmaceutical [2] - Excluding the impairment impact, the core business net profit is projected to be between 60 million and 80 million yuan, indicating stabilization in core operations [2]. Company Status - The goodwill impairment stems from unmet performance commitments following the acquisition of Anhui Hengxing Pharmaceutical in 2021, with ongoing litigation regarding a 256 million yuan payment to the original equity transferor, creating uncertainty [3]. - The company plans to enhance capacity, expand channels, and optimize product structure for the involved subsidiaries to gradually improve profitability [3]. Capacity Expansion - In November 2025, the company launched the first production line for peritoneal dialysis solution at its Rizhao factory, increasing annual capacity to 51 million bags, with a second line under testing that will raise total capacity to 62 million bags, reinforcing market supply capabilities [4]. - The renal business remains a strategic focus, with sales and revenue from peritoneal dialysis solutions continuing to grow in 2025 [4]. Executive Changes - In December 2025, a major shareholder, Huaren Century Group, reduced its stake from 7.06% to 6.83%, which the company stated did not affect control or operations [5]. - The company experienced an unexpected change in leadership when Chairman Zhang Li resigned for personal reasons on August 26, with Director Hou Ruipeng assuming responsibilities, described as a personal matter by the company [5]. Strategic Advancement - The company is advancing its "raw materials + formulations + packaging" integrated strategy, enhancing production efficiency through digital upgrades and expanding into high-value product matrices in respiratory and narcotic fields to address pricing pressures from centralized procurement policies [6]. - In 2025, the company obtained multiple product approvals and patents to strengthen its long-term competitiveness [6].

Group 1 - The company, Huaren Pharmaceutical (300110.SZ), currently has no related testing products available [1]

Financial Performance Expectations - The company expects a net profit of -48,000 to -36,000 thousand yuan for the fiscal year 2025, representing a year-on-year improvement of 64.92% to 73.69% from the previous year's loss of 136,847.90 thousand yuan[3] - The net profit after deducting non-recurring gains and losses is projected to be -49,000 to -37,000 thousand yuan, with a year-on-year increase of 64.45% to 73.15% compared to last year's loss of 137,819.20 thousand yuan[3] - The company expects to achieve a net profit of 6,000 to 8,000 thousand yuan for 2025, excluding the impact of goodwill impairment[6] Factors Affecting Profitability - The decrease in net profit is primarily due to the absence of significant credit impairment losses from receivables in the current period, which affected the previous year's loss base[5] - The sales prices of some products have decreased due to drug pricing policies, impacting gross margins, but the company's operational fundamentals remain stable[6] - The company anticipates goodwill impairment of 440,000 to 540,000 thousand yuan due to underperformance of subsidiaries, which will be finalized after assessment and audit[5] Strategic Plans - The company plans to enhance production capacity, expand sales channels, and develop new products to improve profitability and sustainable development[6] Legal and Financial Uncertainties - There is significant uncertainty regarding ongoing litigation related to equity transfer disputes involving a subsidiary, which may affect future financial data[7] - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited[7]

Group 1 - The core viewpoint of the article is that Huaren Pharmaceutical acknowledges that stock price fluctuations in the secondary market are influenced by multiple factors [1] - The company's management emphasizes a commitment to long-term development and shareholder interests [1] - Huaren Pharmaceutical plans to continue efforts to improve operational quality and accelerate measures to enhance profitability [1] Group 2 - The company aims to increase the investment value of the listed company and enhance the level of returns for investors [1]